The Ohio State University | Strategic Alliance Partners

Latest from The Ohio State University


Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19, 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.